1.22

5.17% 0.06

After Hours: 1.13 -0.09 -7.38%

Indaptus Therapeutics Inc (INDP)

Overview News Price History Financials Discussions Forecast

Indaptus Therapeutics Inc stock is traded at $1.22, with a volume of 131.89K. It is up +5.17% in the last 24 hours and down -10.29% over the past month. Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Previous Close:

$1.16

Open:

$1.2

24h Volume:

131.89K

Relative Volume:

0.11

Market Cap:

$162.56M

Revenue:

Net Income/Loss:

$-18.86M

P/E Ratio:

-0.076

EPS:

-16.054

Net Cash Flow:

$-17.68M

1W Performance:

+7.02%

1M Performance:

-10.29%

6M Performance:

-39.30%

1Y Performance:

-73.54%

1-Day Range:

$1.17

$1.235

1-Week Range:

$1.09

$1.235

52-Week Range:

$0.92

$8.57

Indaptus Therapeutics Inc Stock (INDP) Company Profile

Name

Indaptus Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(646) 427-2727

Address

3 COLUMBUS CIRCLE, NEW YORK

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

INDP's Discussions on Twitter

Compare INDP vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INDP Indaptus Therapeutics Inc	1.22	183.87M	0	-18.86M	-17.68M	-16.05
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Indaptus Therapeutics Inc Stock (INDP) Latest News

Sep 04, 2026

Indaptus Therapeutics Announces Routine Board Member Resignation - TipRanks

Sep 04, 2026

Indaptus Therapeutics, Inc. Announces Resignation of Tim Ruan from Director, Effective September 2, 2026 - marketscreener.com

Sep 04, 2026

Sep 01, 2026

Indaptus Updates ATM Agreement to Expand Capital Flexibility - TipRanks

Sep 01, 2026

Indaptus Therapeutics Launches $100 Million ATM Equity Program With H.C. Wainwright - TradingView

Sep 01, 2026

Indaptus sets up $100M at-the-market stock program - Stock Titan

Sep 01, 2026

Aug 31, 2026

Indaptus Therapeutics Launches $100M ATM Offering at $1.14 Per Share (NASDAQ: INDP) - Kalkine Media

Aug 31, 2026

Aug 26, 2026

Indaptus Therapeutics, Inc. SEC Filing (Aug 26, 2026) - Stock Titan

Aug 26, 2026

Aug 20, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Aug 20, 2026

Aug 14, 2026

Indaptus Therapeutics Stock Price Forecast. Should You Buy INDP? - StockInvest.us

Aug 14, 2026

Indaptus Therapeutics Inc (NASDAQ: INDP) Share Price, INDP Stock News, INDP Share Price & Updates - Kalkine

Aug 14, 2026

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1% - MarketBeat

Aug 14, 2026

Aug 13, 2026

Indaptus Therapeutics, Inc. 2Q 2026: Net loss $(1.79M), EPS $(0.02) — 10-Q Summary - TradingView

Aug 13, 2026

Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2 - Stock Titan

Aug 13, 2026

Indaptus Q2 Net Loss Narrows to $1.8 Million - Quiver Quantitative

Aug 13, 2026

Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise - Stock Titan

Aug 13, 2026

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Aug 13, 2026

Indaptus Therapeutics (INDP) Falls 14% to $1.02 — Biotech Micro-Cap Tests Critical SupportDescending Triangle - vinanet.vn

Aug 13, 2026

Aug 12, 2026